| # | Drug | Count |
|---|---|---|
| 0 | PALBOCICLIB | 10628 |
| 1 | LETROZOLE | 2803 |
| 2 | LETROZOLE TABLETS | 2450 |
| 3 | FULVESTRANT | 2129 |
| 4 | SUNITINIB MALATE | 2021 |
| 5 | CARBOPLATIN | 1620 |
| 6 | CYCLOPHOSPHAMIDE | 1547 |
| 7 | CYCLOPHOSPHAMIDE FOR INJECTION | 1547 |
| 8 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 1547 |
| 9 | AXITINIB | 1323 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | BEVACIZUMAB-BVZR | 82 | 0.1239 |
| 1 | DYCLONINE HYDROCHLORIDE | 11 | 0.1158 |
| 2 | PALBOCICLIB | 10628 | 0.1136 |
| 3 | DACOMITINIB | 78 | 0.1064 |
| 4 | TALAZOPARIB | 171 | 0.1040 |
| 5 | LORLATINIB | 630 | 0.1034 |
| 6 | CRIZOTINIB | 1115 | 0.0894 |
| 7 | AXITINIB | 1323 | 0.0697 |
| 8 | FULVESTRANT | 2129 | 0.0674 |
| 9 | GLASDEGIB | 28 | 0.0601 |
| # | Drug class | Count |
|---|---|---|
| 0 | Kinase Inhibitor [EPC] | 16239 |
| 1 | Aromatase Inhibitor [EPC] | 3904 |
| 2 | Platinum-based Drug [EPC] | 2982 |
| 3 | Nucleoside Metabolic Inhibitor [EPC] | 2858 |
| 4 | Corticosteroid [EPC] | 2634 |
| 5 | Alkylating Drug [EPC] | 2266 |
| 6 | Estrogen Receptor Antagonist [EPC] | 2204 |
| 7 | Microtubule Inhibitor [EPC] | 1735 |
| 8 | Nonsteroidal Anti-inflammatory Drug [EPC] | 1480 |
| 9 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 1296 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Estrogen Receptor Antagonist [EPC] | 2204 | 0.0573 |
| 1 | CD22-directed Immunoconjugate [EPC] | 155 | 0.0553 |
| 2 | Aromatase Inhibitor [EPC] | 3904 | 0.0361 |
| 3 | Kinase Inhibitor [EPC] | 16239 | 0.0306 |
| 4 | Glycolipid Disialoganglioside-directed Antibody [EPC] | 28 | 0.0283 |
| 5 | Interleukin-6 Antagonist [EPC] | 13 | 0.0227 |
| 6 | Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] | 9 | 0.0188 |
| 7 | Adrenal Steroid Synthesis Inhibitor [EPC] | 16 | 0.0181 |
| 8 | Actinomycin [EPC] | 37 | 0.0172 |
| 9 | CD123 Interaction [EPC] | 8 | 0.0165 |